|
gptkbp:instanceOf
|
gptkb:drug
Bruton tyrosine kinase inhibitor
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
gptkb:TGA
|
|
gptkbp:ATCCode
|
L01EL03
|
|
gptkbp:brand
|
gptkb:Brukinsa
|
|
gptkbp:CASNumber
|
1691249-45-6
|
|
gptkbp:chemicalFormula
|
C27H29N5O3
|
|
gptkbp:contraindication
|
hypersensitivity to zanubrutinib
|
|
gptkbp:developer
|
gptkb:BeiGene
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminatedIn
|
renal
biliary
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(N=C1)N2CCN(CC2)C3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5)C(=O)NC6=CC=CC=C6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zanubrutinib
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits Bruton tyrosine kinase
|
|
gptkbp:metabolism
|
gptkb:liver_(CYP3A)
|
|
gptkbp:molecularWeight
|
471.55 g/mol
|
|
gptkbp:patent
|
gptkb:BeiGene
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
not recommended
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
94%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
11708507
DB15035
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:pneumonia
diarrhea
hypertension
rash
neutropenia
thrombocytopenia
hemorrhage
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:Bruton_tyrosine_kinase
|
|
gptkbp:UNII
|
Q3Z5X4D8V6
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
gptkb:small_lymphocytic_lymphoma
gptkb:Waldenström's_macroglobulinemia
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:Servier_Pharmaceuticals
gptkb:Mantle_Cell_Lymphoma
|
|
gptkbp:bfsLayer
|
7
|